Immunogen design to focus the B-cell repertoire

Current Opinion in HIV and AIDS

Volumn 9, Issue 3, 2014, Pages 217-223

  Sattentau, Quentin J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Affinity maturation; B cell receptor; broadly neutralizing antibody; HIV 1 envelope glycoproteins

Indexed keywords

B LYMPHOCYTE RECEPTOR; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; ENGINEERING; EVOLUTION; HUMAN IMMUNODEFICIENCY VIRUS 1; MATURATION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS;

EID: 84898548356     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000054     Document Type: Review

References (68)

1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-1065.
2. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
3. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
4. Roederer M, Keele BF, Schmidt SD, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014; 505:502-508.
5. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for anHIV-1 vaccine: the end ofthe beginning. Nat Rev Immunol 2013; 13:693-701.
6. Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337:183-186.
7. Mouquet H, Nussenzweig MC. HIV: roadmaps to a vaccine. Nature 2013; 496:441-442.
8. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012; 109:18921-18925.
9. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
10. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81-84.
11. Johnson PR, Schnepp BC, Zhang J, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-906.
12. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122.
13. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
14. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
15. Tran EE, Borgnia MJ, Kuybeda O, et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 2012; 8:e1002797.
16. Bartesaghi A, Merk A, Borgnia MJ, et al. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol 2013; 20:1352-1357.
17. Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1477-1483.
18. Lyumkis D, Julien JP, de Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1484-1490.
19. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659.
20. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678-682.
21. West AP Jr, Diskin R, Nussenzweig MC, et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 2012; 109:E2083-E2090.
22. Scharf L, West AP Jr, Gao H, et al. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci USA 2013; 110:6049-6054.
23. Zhou T, Zhu J, Wu X, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013; 39:245-258.
24. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333:1593-1602.
25. Sanders RW, Derking R, Cupo A, et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not nonneutralizing antibodies. PLoS Pathog 2013; 9:e1003618.
26. Julien JP, Lee JH, Cupo A, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 2013; 110:4351-4356.
27. Chen L, Kwon YD, Zhou T, et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009; 326:1123-1127.
28. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
29. McLellan JS, Pancera M, Carrico C, et al. Structure of HIV-1 gp120V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480:336-343.
30. Crooks ET, Tong T, Osawa K, et al. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 2011; 85:5825-5839.
31. Tong T, Crooks ET, Osawa K, et al. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 2012; 86:3574-3587.
32. Kong L, Sattentau QJ. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clinic Res 2012; S8-003:1-11.
33. Calarese DA, Scanlan CN, Zwick MB, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300:2065-2071.
34. Kong L, Lee JH, Doores KJ, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013; 20:796-803.
35. Pejchal R, Doores KJ, Walker LM, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334:1097-1103.
36. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
37. Mouquet H, Scharf L, Euler Z, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 2012; 109:E3268-E3277.
38. Kim M, Sun ZY, Rand KD, et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 2011; 18:1235-1243.
39. Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009; 106:20234-20239.
40. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491:406-412.
41. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol 2010; 28:185-210.
42. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112:1570-1580.
43. + memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013; 39:758-769.
44. Haynes BF, Kelsoe G, Harrison SC, et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30:423-433.
45. Breden F, Lepik C, Longo NS, et al. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 2011; 6:e16857.
46. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153:126-138.
47. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469-476.
48. Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828-4840.
49. Xiao X, Chen W, Feng Y, et al. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009; 1:802-817.
50. Xiao X, Chen W, Feng Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycopro-teins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009; 390:404-409.
51. Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 1998; 8:751-759.
52. Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013; 9:e1003106.
53. McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013; 210:655-663.
54. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
55. Bonsignori M, Hwang KK, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. JVirol 2011; 85:9998-10009.
56. Pancera M, McLellan JS, Wu X, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010; 84:8098-8110.
57. Georgiev IS, Rudicell RS, Saunders KO, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 2014; 192:1100-1106.
58. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012; 2:2.
59. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-1637.
60. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711-716.
61. Ringe RP, Sanders RW, Yasmeen A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci USA 2013; 110:18256-18261.
62. Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glyco-peptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA 2013; 110:18214-18219.
63. Amin MN, McLellan JS, Huang W, et al. Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies. Nat Chem Biol 2013; 9:521-526.
64. Aussedat B, Vohra Y, Park PK, et al. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J Am Chem Soc 2013; 135:13113-13120.
65. Corti D, Langedijk JP, Hinz A, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5:e8805.
66. Hraber P, Seaman MS, Bailer RT, et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014; 28:163-169.
67. Georgiev IS, Doria-Rose NA, Zhou T, et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 2013; 340:751-756.
68. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-598.